

New Drug Approvals

Generic Name (Trade Name—Company)

August 28, 2018

Eravacycline

(*Xerava*—*Tetraphase Pharmaceuticals*)

New agent approved for treatment of cIAI in patients aged 18 years and older

Uses/Notes

Tetraphase Pharmaceuticals announced FDA approval of [eravacycline](#) for the treatment of complicated intra-abdominal infections (cIAI) in patients aged 18 years and older.

In clinical trials, eravacycline was well tolerated and achieved high clinical cure rates in patients with cIAI, demonstrating statistical noninferiority to two widely used comparators—ertapenem and meropenem.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of eravacycline and other antibacterial drugs, eravacycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

Eravacycline is contraindicated for use in patients with known hypersensitivity to eravacycline or to tetracycline-class antibacterial drugs. Life-threatening hypersensitivity reactions have been reported with use of the drug.

The most common adverse reactions observed in clinical trials (incidence \geq 3%) were infusion-site reactions, nausea, and vomiting.

Source URL:

<http://aphanet.org/new-drug-approvals/new-agent-approved-treatment-ciai-patients-aged-18-years-and-older>

APhA DrugInfoLine is an official publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not necessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that information contained in APhA DrugInfoLine is accurate and current; however, they shall have no liability to any person or entity with regard to claims, losses, or damages caused or alleged to be caused, directly or indirectly, by use of any information contained in the publication. All decisions about drug therapy must be based on the independent judgment of the clinician. Copyright © 2000–2011, American Pharmacists Association. All rights reserved.